Genetron Holdings is an oncology company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. Co. has developed a product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. Depending on the nature of cancer and service types, Co. offers tissue biopsy, liquid biopsy, or both. Co. also offers end-to-end comprehensive genomic profiling solution for global biopharmaceutical companies to support their research and drug development. The GTH stock yearly return is shown above.
The yearly return on the GTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|